STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment

Robert H. Jones, MD,* Harvey White, MB, CthB, DSc,|| Eric J. Velazquez, MD,† Linda K. Shaw, MHS,§ Ricardo Pietrobon, MD, PtID,¶ Julio A. Panza, MD,# Robert O. Bonow, MD,** George Sopko, MD,†† Christopher M. O'Connor, MD,† Jean-Lucien Rouleau, MD‡‡

Durham, North Carolina; Auckland, New Zealand; Singapore; Washington, DC; Chicago, Illinois; Bethesda, Maryland; and Montreal, Quebec, Canada

Objectives
The aim of this study was to assess the influence of enrolling site location and enrollment performance on the generalizability of STICH (Surgical Treatment for Ischemic Heart Failure) trial results.

Background
The international STICH trial seeks to define the role of cardiac surgery for patients with ischemic cardiomyopathy.

Methods
Baseline characteristics of 2,136 randomized STICH patients were entered into a multivariate equation created using the Duke Databank for Cardiovascular Diseases to predict their 5-year risk for death without cardiac surgery. Patients ordered by increasing predicted risk were assigned to 1 of 32 risk at randomization (RAR) groups created to share one-thirty-second of total predicted deaths. Numbers of patients sharing the same RAR group were compared between higher and lower enrolling site groupings and for countries tending to enroll high- or low-risk patients.

Results
Country of enrollment was a stronger determinant of risk diversity than site enrollment performance among patients enrolled at 127 sites in 26 countries. Mean RAR differences among countries ranged from 9.4 (Singapore) to 18.6 (Germany). However, 1,614 of 2,136 patients (76%) from countries enrolling lower-risk patients shared the same RAR group with patients from countries enrolling higher-risk patients. Baseline characteristics responsible for risk differences of patients enrolled in the 2 country groupings were sufficiently similar to exert little influence on clinical decision making.

Conclusions
STICH randomized patients are characterized by a continuous spectrum of risk, without discordant dominance from any site or country. Clinical site diversity promises to enhance the generalization of STICH trial results to a broad population of patients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease; NCT00023595) (J Am Coll Cardiol 2010;56:490–8) © 2010 by the American College of Cardiology Foundation

The National Institutes of Health–funded international STICH (Surgical Treatment for Ischemic Heart Failure) trial addresses 2 hypotheses to assess the value of cardiac surgery in patients with ischemic cardiomyopathy (1). The recently reported outcome of the surgical ventricular reconstruction (SVR) hypothesis confirmed that adding SVR to coronary artery bypass grafting (CABG) in patients with anterior left ventricular (LV) dysfunction decreased LV volume more than CABG alone but did not reduce death or cardiac hospitalization (2). Cardiovascular specialists have raised questions about whether the spectrum of severity of disease at the time of randomization was sufficiently broad to include all patients who might receive survival benefit from SVR (3). Data from patients now being followed in the surgical revascularization hypothesis will definitively answer whether or not CABG added to evidence-based medical therapy (MED) increases the survival of patients with ischemic cardiomyopathy. This answer will clarify

See page 508
whether an ischemia diagnosis and interventional treatment should be pursued in patients presenting with heart failure symptoms or asymptomatic systolic dysfunction. The importance of STICH trial findings to guide appropriate care decisions for future patients demands an answer to the question: how generalizable are STICH trial results to the patients I see?

The STICH protocol enrollment criteria ensured patient safety and excluded patients without ischemic cardiomyopathy as the most likely cause of death during follow-up. Thereafter, responsible physicians selected 1 of 3 randomization strata, each of which included possible randomization to a cardiac surgical option with significant short-term risk. Patient enrollment was difficult. Variation in equipoise among clinicians and clinical site diversity of structure and care processes produced a broad range of randomization rates. Incremental geographic expansion over 3 years caused enrollment duration to vary among sites. Clinical site location has been shown to influence characteristics of enrolled populations (4). That STICH was among the top 10 of 129 ongoing clinical trials (7.9%) during 2005 randomized patients in 20 or more countries (5) emphasizes the need to assess whether enrolling site diversity helped or hindered the generalization of STICH conclusions. The diversity of STICH sites could have aggregated multiple subgroups into discontinuous patient groupings with dissimilar risk. Alternatively, random individual patient diversity both within and among sites could produce a population with a smooth gradation of risk severity. A patient-based metric of baseline risk is needed to document the influence of enrollment decisions made by many physicians in different clinical care environments.

This report describes the STICH risk at randomization (RAR) index, which reflects baseline clinical risk of each patient in context with the full risk spectrum of all randomized patients. Clinical site enrollment rates and geographic location influence on the total randomized patient cohort risk spectrum are compared using the numbers of randomized patients who share the same RAR index number when grouped by clinical site characteristics. Clinical data tabulated from RAR groups created to show the greatest baseline risk discordance place the variability among enrolling sites in clinical context.

Methods

Clinical site and patient recruitment. In 2002, 23 U.S., 7 Canadian, and 2 European clinical sites selected for expertise in clinical research and outstanding care of patients with ischemic cardiomyopathy were activated. Persistently low patient enrollment required incremental expansion that concluded in 2005 with 171 activated clinical sites. Clinical sites were expected to enroll patients into both hypotheses, except for the last sites invited in Argentina, India, and the U.K. These sites were recruited to enroll patients only into the surgical revascularization hypothesis because their help was not needed to attain the 1,000-patient SVR hypothesis recruitment goal. During the 3 years of incremental expansion, 44 activated clinical sites were deactivated by mutual consent because of their inability to enroll any patient.

LV ejection fraction ≤0.35 and coronary artery disease (CAD) amenable to CABG were entry criteria for all STICH patients. Major cardiac disease exclusions were a recent myocardial infarction and need for aortic valve replacement. Any noncardiac disease sufficiently severe to dominate expected 3-year longevity excluded patients. Study design required all STICH patients to receive MED. Patients with Canadian Cardiovascular Society class III or greater ongoing angina on MED and/or ≥50% left main stenosis were not eligible for randomization to MED as their only treatment. Eligibility for SVR required dominant anterior akinesia or dyskinesia amenable to SVR. Patients ineligible for SVR but eligible to receive MED with or without CABG were randomized in stratum A. Patients ineligible for MED alone but eligible to receive CABG with or without SVR were randomized in stratum C. Patients eligible for all 3 treatments were randomized in stratum B. All stratum A and stratum B patients randomized to MED with or without CABG were analyzed in the surgical revascularization hypothesis. All stratum C patients and stratum B patients randomized to CABG with or without SVR were analyzed in the SVR hypothesis.

The clinical judgment of physicians and surgeons responsible for care of STICH-eligible patients determined the enrollment stratum offered for patient consent under the oversight of the ethics committee at each site. The primary ethical concern guiding equipoise for randomization was to offer patients treatment combinations judged to have similar long-term mortalities. Relative benefits of treatment combinations offered within each enrollment stratum might differ among STICH sites. The randomization process stratified treatment assignment by site. Whereas it is not possible to know the underlying enrolling physician judgment used to choose the enrollment stratum, it is possible to map the individual clinical characteristics of enrolled patients to provide evidence of the spectrum of disease severity produced by choices made.

Creation of the RAR index. Three Duke Databank for Cardiovascular Diseases CAD prognosis publications (6–8) identified candidate variables used to create a Cox multivariate regression equation predictive of time to death in 821 STICH-eligible MED Duke Databank for Cardiovascular Diseases patients during 5.5 years of follow-up. Prognostic baseline clinical variables in descending order of importance for predicting time to death in this cohort over a mean follow-up of 5 years were age, renal disease (creat-
inine (≥1.5 mg/dl), heart failure, ejection fraction, Duke CAD index, mitral insufficiency, and cerebrovascular disease (Table 1). Individual STICH patient baseline values for these variables entered into the multivariate equation produced a probability of death for each STICH patient that ranged from 0.18387 to 0.99949. The STICH patients were placed in ascending order of their individual prediction of death. All predicted death estimates summed to 1,001.648 corresponding to a 5-year mortality of 0.469, assuming only MED, not surgical treatment, for the 2,136 STICH randomized patients. Using least squares analysis to minimize differences between groups, 32 groups were created to each share one-thirty-second of total predicted deaths as close as was possible with the constraint that the exact risk of each patient had to be assigned to only 1 group. The numbers of patients in groups 1 to 32 deceased as the predicted risk increased, except for groups 31 and 32, which each had 32 patients (Fig. 1). Total predicted deaths per group ranged from a minimum of 30.89 (RAR group n = 31) to a maximum of 31.67 (RAR group n = 28). The average group mortality ranged from 0.228 in group 1 to 0.989 in group 32. By assigning the average group mortality to each

<table>
<thead>
<tr>
<th>Variable</th>
<th>Parameter Estimate</th>
<th>Standard Error</th>
<th>Chi-Square</th>
<th>p Value</th>
<th>Hazard Ratio</th>
<th>Variable Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.27836</td>
<td>0.04339</td>
<td>41.1562</td>
<td>&lt;0.0001</td>
<td>1.321</td>
<td>Yrs (HR by 10 yrs)</td>
</tr>
<tr>
<td>Renal disease</td>
<td>1.27632</td>
<td>0.26594</td>
<td>23.0321</td>
<td>&lt;0.0001</td>
<td>3.583</td>
<td>Creatinine ≥1.5 mg/dl</td>
</tr>
<tr>
<td>Heart failure</td>
<td>0.10669</td>
<td>0.02768</td>
<td>14.8579</td>
<td>0.0001</td>
<td>1.113</td>
<td>NYHA functional class</td>
</tr>
<tr>
<td>Ejection fraction</td>
<td>-0.11904</td>
<td>0.03190</td>
<td>13.9255</td>
<td>0.002</td>
<td>0.888</td>
<td>% (HR per 5)</td>
</tr>
<tr>
<td>CAD index</td>
<td>0.00582</td>
<td>0.00184</td>
<td>10.0175</td>
<td>0.0016</td>
<td>1.006</td>
<td>0–100</td>
</tr>
<tr>
<td>Mitral insufficiency</td>
<td>0.10521</td>
<td>0.03559</td>
<td>8.7393</td>
<td>0.0031</td>
<td>1.111</td>
<td>0 (none)–4 (severe)</td>
</tr>
<tr>
<td>History of cerebrovascular disease</td>
<td>0.26897</td>
<td>0.10504</td>
<td>6.5565</td>
<td>0.0105</td>
<td>1.309</td>
<td>Stroke or equivalent</td>
</tr>
</tbody>
</table>

CAD = coronary artery disease; NYHA = New York Heart Association; RAR = risk at randomization.
patient in each group, every patient carries a marker of his or her predicted risk in the context of the entire randomized population. The RAR of each patient provides a tool to evaluate the impact of clinical site location and enrollment performance on the spectrum of risk of all patients enrolled. Creation of the RAR index only ordered patients by baseline risk, without disrupting randomized status within RAR groups. Therefore, each patient may be considered to be an interchangeable courier of equivalent baseline risk when compared by clinical site characteristics within his or her RAR grouping.

Analysis of clinical site location and performance on risk spectrum of enrolled patients. The RAR profiles of 2 dichotomous separations of the 2,136 STICH total patients were compared for the numbers of patients who shared each RAR interval. The RAR profile of 1,057 patients enrolled by the 13 highest enrolling sites was compared to the RAR profile of 1,078 patients from the 114 lowest enrolling sites. To evaluate the influence of enrolling country on the risk distribution of patients, a mean patient-weighted RAR was calculated to reflect the average risk of all patients enrolled in each country. The sum resulting from multiplying the RAR index number of each patient enrolled in each country when divided by total number of all enrolled patients in each country provided the mean patient-weighted RAR for that country. Patients from 3 countries (Belgium, Greece, and Turkey) enrolling only 1 patient each were grouped with the 4 patients enrolled in Malaysia to provide a single patient-weighted mean RAR for the 4 lowest enrolling countries. Arranging countries in ascending order of patient-weighted mean RAR identified Sweden (n = 22) to separate 7 countries with lower mean RAR that enrolled 1,057 patients from the 18 countries with higher mean RAR that enrolled 1,057 patients. The 7 lower-risk patients from Sweden added to the 1,057 patients from lower-risk countries brought the number of patients in the lower-risk country grouping to 1,064. The 15 higher-risk patients added to the 1,057 patients from higher-risk countries brought the total to 1,072 patients in the higher-risk cohort. In RAR zones 1 to 12, clinical sites with lower mean RAR enrolled most patients. In RAR zones 22 to 32, countries with higher mean RAR enrolled most patients. In RAR zones 13 to 21, both country groupings enrolled similar patients. For each of these 3 RAR zone groupings, baseline clinical characteristics of patients from countries tending to enroll high-risk patients were compared with those of patients from countries tending to enroll low-risk patients.

Results

Patient enrollment. Between July 24, 2002, and May 5, 2007, 127 sites in 26 countries randomized 2,136 patients. On the basis of clinical decisions and protocol guidelines, 1,277 of 2,136 randomized patients (60%) (stratum A + stratum B) were eligible for MED alone, and 1,075 of the 2,136 patients (50%) (stratum B + stratum C) were SVR eligible (Fig. 2). A relatively smooth profile of decline in the number of patients was observed throughout the RAR risk spectrum (Fig. 3). The median age steadily increased from 48 to 74 years, and the median ejection fraction decreased from 0.30 to 0.20 over the 32 RAR groups.

The same RAR group was shared by 890 of the 1,057 patients (84%) from higher enrolling sites and 82% of 1,078 patients from lower enrolling sites (Fig. 4). The 167 unmatched patients from the higher enrolling sites were predominantly lower-risk patients. The 189 unmatched patients from the lower enrolling sites were predominantly higher-risk patients. There was no consistent relationship between total patient enrollment in each country and the patient-weighted mean RAR index by enrolling country (Fig. 4). Poland and Russia dominated the enrollment of lower-risk patients, and the U.S. and Canada led countries enrolling higher-risk patients. RAR profiles showed that 807 of 1,064 patients (76%) from countries enrolling lower-risk patients matched 807 of 1,072 patients (75%) from countries enrolling higher-risk patients (Fig. 5). However, the RAR profile identified 3 patterns of unmatched patients. In RAR groups 1 to 12, all unmatched patients were from countries enrolling lower-risk patients. RAR groups 13 to 21 showed similar numbers of unmatched patients from both country groupings. In RAR groups 22 to 32, all unmatched patients were from countries enrolling higher-risk patients. Baseline clinical characteristics tabulated for these 3 RAR patient groupings demonstrated statistically significant differences between patients in the lowest and highest RAR groupings, with less difference among patients in RAR groups 13 to 21 (Table 2). However, the magnitude of statistically significant differences of patients related to country of enrollment appeared sufficiently small to be of little clinical significance in application of STICH results to care decisions for future patients with ischemic cardiomyopathy.

Discussion

The Northern New England Cardiovascular Disease Study Group identified patients with poor LV function to have the greatest inconsistency of CABG use compared with guideline recommendations (9). STICH investigators experienced this divergence of opinion when patients who were STICH eligible by protocol were presented at investigator meetings. Difference in zones of equipoise among physicians responsible for enrolling patients at individual sites combined to produce a smooth risk profile for the entire STICH population. The 4-fold decline in numbers of patients over the 32 RAR groups created with equivalent predicted deaths produced a STICH patient risk profile familiar to clinicians. Ischemic cardiomyopathy as the highest risk subset of all chronic CAD diagnoses includes a rapidly declining number of patients in each RAR group that reflects the highest risk tail of a normal distribution of
all patients with CAD truncated by an ejection fraction \( \leq 0.35 \) applied as a STICH entry criterion.

Enrollment performance varied greatly among sites and was strongly related to baseline clinical risk. The highest enrolling sites tended to enroll more low-risk patients. The lowest-enrolling sites tended to enroll more high-risk patients. The patient risk zone that corresponded to the equipoise zone of the responsible physician appeared to be the strongest determinant of baseline risk of enrolled patients at a site. The profile of the RAR patient distribution suggests that small differences in equipoise windows positioned toward the low- or high-risk direction could produce substantial changes in numbers of patients considered eligible for randomization. Many more low-risk patients than high-risk patients were available if sites were willing to randomize them. However, RAR data confirm that 85% of enrolled patients had similar predicted risk even when clinical sites were grouped by those sites with lowest or highest enrollment performance. Moreover, both site performance groupings enrolled some patients into each RAR group.

Country differences in population demographics also may influence the numbers of low- or high-risk patients presenting with STICH eligibility criteria. The World Health Organization has reported age-standardized mortality rates for cardiovascular disease per 100,000 population to be 324 for Poland and 688 for Russia, the 2 highest enrolling countries of the 7 countries tending to enroll low-risk patients, in contrast to rates of 188 for the U.S. and 141 for Canada, the 2 highest enrolling of the 18 countries tending to enroll more high-risk patients. Country demographics, health care availability, and equipoise differences among physicians most likely contributed in varying degrees to produce observed variation in patient risk among enrolling countries. However, sufficient similarity of patient baseline risk among all enrolling countries has been demonstrated to suggest that STICH enrollment of patients in 26 countries should enhance the generalization of STICH trial results to a broad spectrum of future patients with ischemic cardiomyopathy throughout the world.

The use of a multivariate equation to stratify baseline risks of randomized patients into low-risk, middle-risk, and high-risk groups was first reported by the Veterans Administration Cooperative Study Group in 1981 (10). Treatment effect was confined to only the high-risk cohort. This early work changed patient selection criteria for CABG from low- to high-risk patients and set the precedent for modeling of baseline

---

**Figure 2** Schema of Patient Enrollment

This schematic depiction of the STICH (Surgical Treatment for Ischemic Heart Failure) trial design includes numbers of patients randomized to each stratum. Treatment assignments were evidence-based medical therapy (MED) only for 602 patients, coronary artery bypass grafting (CABG) added to MED for 1,033 patients, and CABG and surgical ventricular reconstruction (SVR) added to MED for 501 patients. The 76 stratum B patients assigned to MED plus CABG treatment were used to address both the surgical revascularization hypothesis and the SVR hypothesis. Therefore, 2,136 randomized patients provided 2,212 patients with potential for primary end points for analysis of either or both hypotheses. CAD = coronary artery disease; EF = ejection fraction.
Figure 3 Patients and Corresponding Clinical Characteristics by RAR

Histogram depicting individual patients at each RAR interval. The corresponding median age, ejection fraction (EF), and Duke coronary artery disease (CAD) index for each risk at randomization (RAR) group and the percent of patients in each RAR group with baseline creatinine (CR) >1.5 mg/dl, New York Heart Association (NYHA) functional class III to IV heart failure (HF), diabetes, mitral regurgitation 3 to 4+, and vascular disease provided a comprehensive summary of the components of risk for the entire population.
Countries ranked by the patient-weighted risk at randomization (RAR) mean show a 2-fold range of difference from the lowest mean of 9.4 (Singapore) to the highest mean of 18.6 (Germany). The number of patients enrolled in each country and cumulative patient enrollment by increasing RAR show the diversity of enrollment performance by country throughout the spectrum of patient risk of enrolling countries. The patient-weighted mean RAR index was calculated by multiplying the number of patients enrolled by each country by the index number of each RAR interval. The sum of these products was divided by the total number of patients enrolled by that country to produce the patient-weighted mean RAR. *4 countries with few patients (Belgium 1, Greece 1, Turkey 1, Malaysia 4) combined. SVR = surgical ventricular reconstruction.
characteristics of randomized patients to define their relative risk. The present work represents the first individualized patient-based RAR index used to describe the full risk spectrum of a randomized trial cohort.

Study limitations. Predicted mortality of STICH-eligible patients in the Duke Databank for Cardiovascular Diseases may not accurately reflect the mortality of STICH patients treated in other health care settings. However, the RAR

**Figure 5** RAR Profile by Country Mean Patient Risk

A total of 1,614 of 2,136 patients (76%) shared the same risk at randomization (RAR) grouping despite the intentional creation of 2 cohorts to maximize imbalance among countries on the basis of the average baseline risk of patients randomized. RAR groups 1 to 12 included more patients from countries with low patient-weighted mean RAR, and RAR groups 22 to 32 included more patients from countries with high patient-weighted mean RAR. RAR groups 10 to 21 reflected the most even distribution of patients from the 2 country groupings of sites. The baseline characteristics of patients in these 2 groupings are compared in Table 1.

**Table 2** Comparison of Baseline Clinical Characteristics in 3 RAR Groupings by Enrollment by Clinical Sites in Low Patient-Weighted Mean RAR (Low-RAR Countries) With Clinical Sites in High Patient-Weighted Mean RAR (High-RAR Countries)

<table>
<thead>
<tr>
<th>Baseline Clinical Characteristic</th>
<th>RAR Groups 1 to 12</th>
<th>RAR Groups 13 to 21</th>
<th>RAR Groups 22 to 32</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients From Low-RAR Countries</td>
<td>Patients From High-RAR Countries</td>
<td>Patients From Low-RAR Countries</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>66.5 ± 7.4</td>
<td>68.3 ± 8.9</td>
<td>68.5 ± 7.4</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>52.5 ± 2.2</td>
<td>52.8 ± 2.4</td>
<td>52.5 ± 2.2</td>
</tr>
<tr>
<td>CAD severity index</td>
<td>71.1 ± 20.7</td>
<td>66.0 ± 20.9</td>
<td>71.1 ± 20.7</td>
</tr>
<tr>
<td>Chronic renal insufficiency</td>
<td>6 (4.7%)</td>
<td>13 (3.9%)</td>
<td>6 (4.7%)</td>
</tr>
<tr>
<td>NYHA functional class</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>100 (8.5%)</td>
<td>22 (1.8%)</td>
<td>100 (8.5%)</td>
</tr>
<tr>
<td>II</td>
<td>123 (42.3%)</td>
<td>30 (2.4%)</td>
<td>123 (42.3%)</td>
</tr>
<tr>
<td>III</td>
<td>19 (5.3%)</td>
<td>7 (0.6%)</td>
<td>19 (5.3%)</td>
</tr>
<tr>
<td>IV</td>
<td>2 (0.1%)</td>
<td>3 (0.0%)</td>
<td>2 (0.1%)</td>
</tr>
<tr>
<td>Mitral regurgitation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>42 (13.6%)</td>
<td>38 (3.0%)</td>
<td>42 (13.6%)</td>
</tr>
<tr>
<td>1</td>
<td>126 (40.3%)</td>
<td>150 (11.9%)</td>
<td>126 (40.3%)</td>
</tr>
<tr>
<td>2</td>
<td>10 (0.3%)</td>
<td>7 (0.1%)</td>
<td>10 (0.3%)</td>
</tr>
<tr>
<td>3</td>
<td>3 (0.1%)</td>
<td>2 (0.0%)</td>
<td>3 (0.1%)</td>
</tr>
<tr>
<td>4</td>
<td>1 (0.0%)</td>
<td>0 (0.0%)</td>
<td>1 (0.0%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>166 (42.4%)</td>
<td>257 (34.5%)</td>
<td>166 (42.4%)</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD or as n (%).
CAD = coronary artery disease; HF = heart failure; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; RAR = risk at randomization.
grouping order of patients was independent of the numeric accuracy of the risk prediction.

RAR development included site-reported ejection fraction as the only assessment of LV function. Core laboratory assessments of global and regional LV function reported without knowledge of patient treatment will be used to assess the generalizability of STICH results on the basis of the severity of abnormality represented by the SVR hypothesis patients. Many patient-specific clinical variables that influence decisions for cardiac surgery, such as conduit availability and the suitability of coronary arteries for CABG, were not reported for STICH patients. However, all patients randomized were assessed as eligible for either CABG alone or CABG with SVR by STICH surgeons at each clinical site.

Conclusions

The RAR index methodology provides a clinically useful quantitation of the baseline risk spectrum of patients. Clinical site location introduced greater variation on the profile of baseline clinical risk than enrollment performance. However, 76% of patients shared the same risk profile when grouped by randomization in countries that enrolled more high- or low-risk patients. Differences in the baseline characteristics causing site-related differences in the RAR profile were modest and unlikely to hinder the generalizability of STICH results. Diversity among patients randomized by 127 STICH clinical sites appears more likely to enhance the generalizability of STICH trial results.

Acknowledgments

The authors thank Vanessa Moore for her support in preparing the text of this report and Kerry Bassett for her assistance in the design and production of the graphic art essential to illustrate the message of this report.

Reprint requests and correspondence: Dr. Robert H. Jones, Duke University Medical Center, P.O. Box 2986, Durham, North Carolina 27710. E-mail: jones060@mc.duke.edu.

REFERENCES


Key Words: coronary artery bypass grafting • surgical ventricular reconstruction • randomized clinical trial.